NCT02517957 is a Phase 2 clinical trial of Furoic acid loperamide hydrochloride cream in Eczema, sponsored by Shanghai Yueyang Integrated Medicine Hospital.

Who is sponsoring NCT02517957?

NCT02517957 is sponsored by Shanghai Yueyang Integrated Medicine Hospital.

What drugs are being tested in NCT02517957?

Interventions in NCT02517957: Furoic acid loperamide hydrochloride cream, Mullite ointment, 3% boric acid solution, Zine oxide.

Is NCT02517957 still recruiting?

NCT02517957 is currently status unknown. Last updated 6 August 2015.

Last reviewed 2015-08-06 · How we verify

NCT02517957

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research

Status unknown Phase 2 Last updated 6 August 2015

What this trial tests

Phase 2 trial testing Furoic acid loperamide hydrochloride cream in Eczema in 342 participants. Status unknown.

Timeline

1 August 2015

Primary endpoint
1 August 2017

Quick facts

Lead sponsor	Shanghai Yueyang Integrated Medicine Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	342
Start date	1 August 2015
Primary completion	1 August 2017

Drugs / interventions tested

Furoic acid loperamide hydrochloride cream — full drug profile →
Mullite ointment — full drug profile →
3% boric acid solution
Zine oxide — full drug profile →

Conditions studied

Eczema — all drugs for Eczema →

Sponsor

Shanghai Yueyang Integrated Medicine Hospital

Who can join

Adults 18 to 65, any sex, with Eczema. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from Baseline in the Eczema Area and Severity Index (EASI) score
Time frame: Baseline and up to week 4 of the follow up phase

Sponsor's own description

On the basis of Xiashi skin surgery clinical experience, this project adopts the multicenter, randomized, double-blind, controlled trial of design type. Objective, normative evaluation of traditional Chinese medicine cool blood latent town effectiveness of therapeutic regimen in the treatment of eczema, security, and control of the relapse of situation, provide high-level evidence-based basis for traditional Chinese medicine treatment of eczema, aims to form suitable for popularization and application of traditional Chinese medicine in the treatment of eczema.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of a Chinese Herbal Medicine, Qinzhuliangxue Granules, for The Treatment of Eczema: A Randomized, Double-Blind, Multi-Center Clinical Trial
Wang R, Zheng Q, Chen Y, Li S, et al · · 2021 · DOI 10.21203/rs.3.rs-989658/v1

Verify or expand the search:

Other recruiting trials for Eczema

Currently open trials in the same condition.

NCT07463079 — Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema · NA · recruiting
NCT06807268 — A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema · Phase 3 · recruiting
NCT07355075 — A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis) · Phase 2 · recruiting
NCT06998446 — Sodium in the Skin and Atopic Dermatitis · recruiting
NCT06994520 — Efficacy of Topical Cannabidiol for Eczema · Phase 2 · active not recruiting

Other Shanghai Yueyang Integrated Medicine Hospital trials

Trials by the same sponsor.

NCT07434076 — Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional · not yet recruiting
NCT07351448 — Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine · not yet recruiting
NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
NCT06922565 — Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis · NA · not yet recruiting
NCT06790940 — Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02517957 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Yueyang Integrated Medicine Hospital
Last refreshed: 6 August 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02517957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing